Printer Friendly

THE IMMUNE RESPONSE CORPORATION PCR ASSAY CORRELATES VIRAL BURDEN WITH CLINICAL STAGE OF HIV INFECTION

 THE IMMUNE RESPONSE CORPORATION PCR ASSAY CORRELATES VIRAL BURDEN
 WITH CLINICAL STAGE OF HIV INFECTION
 SAN DIEGO, March 5 /PRNewswire/ -- The Immune Response Corporation (NASDAQ-NMS: IMNR) announced today that it has shown a correlation between HIV viral burden and the clinical stage of HIV infection using a quantitative PCR assay developed by the company. Patients in more advanced stages of disease, using the Walter Reed staging system, had significantly higher levels of virus in their blood, on average, than patients in the early, asymptomatic stages of disease. These results confirm the findings of other researchers that demonstrate that increased levels of HIV correlate with advanced patient status in this disease. The company believes this correlation supports the use of viral burden as one of several surrogate markers in the current Phase II/III clinical trial with the company's HIV therapeutic vaccine. None of the patients discussed in today's report has been treated with the company's HIV therapeutic vaccine, and the results presented here provide no indication of the efficacy or safety of this product.
 The results of this research are published in the current issue of AIDS Research and Human Retroviruses.
 This paper describes a quantitative polymerase chain reaction (PCR) assay developed by Immune Response to evaluate the amount of HIV DNA in the cells of HIV-infected patients. The reported data indicates that the PCR assay developed by Immune Response is sensitive and reproducible. With this assay, the company can quantitatively measure the level of HIV in a patient's blood. Data from this new PCR assay also correlate with the standard virus isolation assay.
 HIV viral burden, as measured by PCR and more traditional tests, is one of the surrogate markers that will be used to evaluate efficacy of the company's HIV therapeutic vaccine in an ongoing Phase II/III trial sponsored by The Immune Response Corporation and Rhone-Poulenc Rorer Inc. (NYSE: RPR). This trial is designed to evaluate the efficacy of the HIV therapeutic vaccine based upon multiple markers for disease progression in these patients. The company believes that the data presented in today's report support the significance of viral burden as a marker for disease progression and demonstrate the consistent quantitative evaluation possible with the company's PCR assay.
 The Immune Response Corporation is a biopharmaceutical company engaged in the development of proprietary products for the treatment of HIV infection, which leads to AIDS, and for the treatment of certain autoimmune diseases, particularly rheumatoid arthritis, multiple sclerosis and insulin-dependent diabetes.
 -0- 3/5/92 R
 /CONTACT: Steven Basta of The Immune Response Corporation, 619-431-7080/
 (IMNR RPR) CO: The Immune Response Corporation; Rhone-Poulenc Rorer Inc. ST: California IN: MTC SU:


DM-JL -- SD001 -- 5266 03/05/92 08:37 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 5, 1992
Words:449
Previous Article:FEBRUARY SALES UP 20.6 PERCENT AT HI-LO AUTOMOTIVE
Next Article:FLUOR CORP. ANNOUNCES FIRST QUARTER RESULTS
Topics:


Related Articles
THE IMMUNE RESPONSE CORPORATION PCR ASSAY CORRELATES VIRAL BURDEN WITH CLINICAL STAGE OF HIV INFECTION
RESULTS OF HIV IMMUNOTHERAPEUTIC PHASE II/III CLINICAL TRIAL DEMONSTRATE EFFECT ON VIRAL BURDEN IN HIV-INFECTED INDIVIDUALS
THE IMMUNE RESPONSE CORPORATION ANNOUNCES PUBLICATION OF RESULTS FROM PHASE II DOSE-RANGING CLINICAL TRAIL OF HIV IMMUNOTHERAPEUTIC
LONG-TERM FOLLOW-UP DATA PUBLISHED ON INITIAL PATIENTS TREATED WITH REMUNE(TM)
The Immune Response Corporation Announces Publication of REMUNE(TM) Clinical Trial Data
Roche Molecular Systems International Blood Screening Business News.
Roche Molecular Systems Initiates U.S. Clinical Trials Of COBAS AmpliScreen(TM) HBV Test; Researchers: Study to Shed New Light on Highly Infectious,...
Genetic Immunity Announces Data Related to the DermaVir Nanomedicine Patch in the Journal of Immunology.
CEL-SCI Presents Favorable Data for Leaps Vaccine Technology at Prestigious Immunology Conference.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters